Pharming Group N.V. (AMS:PHARM)

Market Cap	1.22B
Revenue (ttm)	308.77M +26.8%
Net Income	325.58K
EPS	0.00
Shares Out	685.15M
PE Ratio	3,745.83
Forward PE	82.03
Dividend	n/a
Ex-Dividend Date	n/a

Volume	22,174,820
Average Volume	20,733,628
Open	1.795
Previous Close	1.780
Day's Range	1.701 - 1.818
52-Week Range	0.656 - 1.818
Beta	0.16
RSI	62.76
Earnings Date	Mar 12, 2026

About Pharming Group

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company’s lead product is RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3Kẟ inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also dev...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1988
• Employees: 404
• Stock Exchange: Euronext Amsterdam
• Ticker Symbol: PHARM

Financial Performance

In 2024, Pharming Group's revenue was $297.20 million, an increase of 21.15% compared to the previous year's $245.32 million. Losses were -$11.84 million, 12.3% more than in 2023.

Financial numbers in USD